Výsledky vyhledávání - "Middleton MR"

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer

Autor: Woodcock, VK, Chen, J-L, Purshouse, K, Butcher, C, Collins, L, Haddon, C, Verrall, G, Elhussein, L, Roberts, C, Tarlton, A, Rei, M, Napolitani, G, Salio, M, Middleton, MR, Cerundolo, V, Crew, J, Protheroe, AS

Publikováno v: BJUI Compass. 4:322-330

Objectives: This study aimed to investigate the anti-PD-1 inhibitor pembrolizumab as a potential agent for use in non-muscle-invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run-in study to assess the safety and tolerability of intraves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad107e8430b9d020e50050bd544b8bc
https://doi.org/10.1002/bco2.220

Zobrazit plný text záznamu

Sensitivity to Immune Checkpoint Blockade and Progression-Free Survival is associated with baseline CD8+ T cell clone size and cytotoxicity

Autor: Isar Nassiri, Fairfax Bp, Rosalin Cooper, A. Verge de Los Aires, Orion Tong, Sharma Pk, Mahé Ea, Watson Ra, Middleton Mr, Taylor Ca, Hélène Ruffieux

Immune checkpoint blockers (ICB) exert their anti-cancer effects via CD8+ T cells, although how responses vary over sub-populations and across clones is incompletely understood. We performed single-cell RNA-sequencing of CD8+ T cells and their recept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7d124c4fec3096d597cc6f27165fcec
https://doi.org/10.1101/2020.11.15.383786

Zobrazit plný text záznamu

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Autor: Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, Gee, B

Publikováno v: Annals of Oncology
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229

Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106bd17e6b41935f029db129ae87e05b
http://europepmc.org/articles/PMC6096737

Zobrazit plný text záznamu

A phase I study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

Autor: Eyre, TA, Collins, GP, Gupta, A, Coupe, N, Sheikh, S, Whittaker, J, Wang, LM, Campo, L, Soilleux, E, Tysoe, F, Cousins, R, La Thangue, N, Folkes, LK, Stratford, MRL, Kerr, D, Middleton, MR

Background: In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462ba0397642be66177ba59f65148c1a

Zobrazit plný text záznamu

VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours

Autor: Cheng, VWT, Soto, M, Khrapitchev, A, Balderas, F, Zakaria, R, Jenkinson, MD, Middleton, MR, Sibson, N

Purpose: A major issue for the effective treatment of brain metastasis is the late stage of diagnosis with existing clinical tools. The aim of this study was to evaluate the potential of vascular cell adhesion molecule-1 (VCAM-1) targeted magnetic re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::161d50c16bbf21a051d38c012ba64dfa

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání